Days af­ter En­her­tu reeled in an­oth­er FDA nod, with the first-ever green light for HER2-low breast can­cer, an­oth­er an­ti­body drug con­ju­gate biotech claims it has se­cured the largest pre­clin­i­cal ADC pact to date for a sin­gle as­set.

As­traZeneca and Dai­ichi Sankyo made waves with their near­ly $7 bil­lion col­lab­o­ra­tion back in spring 2019, but at that point, En­her­tu was al­ready near­ing the FDA’s doors with clin­i­cal da­ta. The lat­est ADC tie-up to en­ter the bio­phar­ma fray cen­ters around a pre­clin­i­cal as­set, Mer­sana Ther­a­peu­tics’ XMT-2056.

Pro­topa­pas called the GSK col­lab­o­ra­tion the “biggest pre­clin­i­cal ADC deal ever” for a sin­gle as­set. Im­muno­Gen, which will hear back from the FDA by Nov. 28 on its own ADC, inked a $1.7 bil­lion biobuck deal with Eli Lil­ly in Feb­ru­ary, but that was for mul­ti­ple po­ten­tial tar­gets.

Mer­sana it­self signed a bil­lion-dol­lar, back­end-heavy deal ear­li­er this year, com­ing to­geth­er with John­son & John­son in a $40 mil­lion up­front agree­ment.

With the up­front cash from GSK and $225.1 mil­lion as of June 30, Mer­sana has enough mon­ey to bankroll op­er­a­tions in­to the first half of 2024, the biotech said Mon­day af­ter the clos­ing bell.

The EMA is putting EU member states on alert over the shortage of two drugs that counter heart attacks due to an uptick in demand.

On Friday, the EMA sent out a warning that two Boehringer Ingelheim drugs are experiencing a shortage: Actilyse and Metalyse. The drugs are used as emergency treatments for adults experiencing acute myocardial infarction, or a heart attack, by dissolving blood clots that have formed in the blood vessels.

Back in April, Amgen said it was encouraged by the solicitor general’s anticipated review of its Supreme Court petition to rehear a Repatha patent case. They’re likely much less optimistic about the outcome now.

Solicitor General Elizabeth Prelogar wrote in a recent 27-page brief that Amgen’s arguments “lack merit and further review is not warranted.”

The case traces back to a suit filed in 2014 against Sanofi and Regeneron’s Praluent, which ended up beating Amgen’s PCSK9 blockbuster Repatha to market by a month just a year later.

At Klick Health’s first Ideas Exchange conference with biotech and pharma industry insiders since before the pandemic began, it was no surprise many conversations included Covid topics. Yet while vaccines and treatments were discussed, so too were the effects on drug development, federal responses, health inequities — and what to do now and next.

George Yancopoulos, chief scientist and cofounder of Regeneron, opened the conference responding to a question from Acorda CEO Ron Cohen about the spotlight on the industry during Covid and some of the “flak” biopharma has taken in the past.